Wes has extensive experience in rare disease and cancer drug discovery and development. He was instrumental in the discovery and development of Ataluren TM for the treatment of Duchene Muscular Dystrophy caused by nonsense mutations.
He has experience helping grow a start-up bio tech compant into a fully integrated pharmaceutical company. In his most previous role, he was an Executive Director leading a team of scientists in multiple drug discovery efforts to treat genetic diseases.
He holds a PhD in genetics from Thomas Jefferson University and did his postdoctoral work at the University of Pennsylvania. Wes has co-authored more than 20 publications and patents in genetic disorders, oncology and RNA biology.
He
Militsu brings a strong interdisciplinary background in neuroscience and UX research, combining scientific expertise with a user-centered approach to innovation. She has played a key role in developing data-driven solutions for small biopharma and biotech organizations, helping translate complex research into actionable insights.
Prior to her work in UX, Militsu contributed to early-stage drug discovery at a biopharmaceutical company, with a focus on rare neurological disorders.
She holds a degree in psychology minoring in neuroscience from Rutgers University. Bridging her scientific training with her passion for human-computer interaction, Militsu has built a career at the intersection of research, design, and technology.
Phillip is a versatile professional with a strong background in software development, business operations and innovation strategy. He has led the development of data driven solutions for small businesses and contributed to building an innovative healthcare platform at Medocity.
With hands on ecperience in managing small businesses and collaborating with early stage startups, Phillip Thrives at the intersection of technology, science and entrepreneurship. His work focuses on creating scalable, intuitive tools that simplify complex processes and drive measurable impact.